PM 1032
Alternative Names: anti-CLDN18.2 x 4-1BB biAb; CLDN18.2 x 4-1BB biAb; PM-1032Latest Information Update: 10 Feb 2025
Price :
$50 *
At a glance
- Originator Biotheus
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 03 Feb 2025 Biotheus has been acquired by BioNTech
- 31 May 2024 Safety, efficacy and pharmacokinetics data from a phase I/II trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 May 2024 Biotheus plans a clinical trial in Solid tumours (Monotherapy, Combination therapy)